Cargando…
BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis
In the present study, we investigated the involvement of the chaperone protein BiP (also known as GRP78 or Hspa5), a master regulator of intracellular proteostasis, in two mouse models of neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). To this end, we us...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621319/ https://www.ncbi.nlm.nih.gov/pubmed/34830414 http://dx.doi.org/10.3390/ijms222212533 |
_version_ | 1784605429229158400 |
---|---|
author | Gómez-Almería, Marta Burgaz, Sonia Costas-Insua, Carlos Rodríguez-Cueto, Carmen Santos-García, Irene Rodríguez-Crespo, Ignacio García, Concepción Guzmán, Manuel de Lago, Eva Fernández-Ruiz, Javier |
author_facet | Gómez-Almería, Marta Burgaz, Sonia Costas-Insua, Carlos Rodríguez-Cueto, Carmen Santos-García, Irene Rodríguez-Crespo, Ignacio García, Concepción Guzmán, Manuel de Lago, Eva Fernández-Ruiz, Javier |
author_sort | Gómez-Almería, Marta |
collection | PubMed |
description | In the present study, we investigated the involvement of the chaperone protein BiP (also known as GRP78 or Hspa5), a master regulator of intracellular proteostasis, in two mouse models of neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). To this end, we used mice bearing partial genetic deletion of the BiP gene (BiP(+/−) mice), which, for the ALS model, were crossed with mutant SOD1 (mSOD1) transgenic mice to generate mSOD1/BiP(+/−) double mutant mice. Our data revealed a more intense neurological decline in the double mutants, reflected in a greater deterioration of the neurological score and rotarod performance, with also a reduced animal survival, compared to mSOD1 transgenic mice. Such worsening was associated with higher microglial (labelled with Iba-1 immunostaining) and, to a lesser extent, astroglial (labelled with GFAP immunostaining) immunoreactivities found in the double mutants, but not with a higher loss of spinal motor neurons (labelled with Nissl staining) in the spinal cord. The morphological analysis of Iba-1 and GFAP-positive cells revealed a higher presence of activated cells, characterized by elevated cell body size and shorter processes, in double mutants compared to mSOD1 mice with normal BiP expression. In the case of the PD model, BiP(+/−) mice were unilaterally lesioned with the parkinsonian neurotoxin 6-hydroxydopamine (6-OHDA). In this case, however, we did not detect a greater susceptibility to damage in mutant mice, as the motor defects caused by 6-OHDA in the pole test and the cylinder rearing test, as well as the losses in tyrosine hydroxylase-containing neurons and the elevated glial reactivity (labelled with CD68 and GFAP immunostaining) detected in the substantia nigra were of similar magnitude in BiP(+/−) mice compared with wildtype animals. Therefore, our findings support the view that a dysregulation of the protein BiP may contribute to ALS pathogenesis. As BiP has been recently related to cannabinoid type-1 (CB(1)) receptor function, our work also opens the door to future studies on a possible link between BiP and the neuroprotective effects of cannabinoids that have been widely reported in this neuropathological context. In support of this possibility, preliminary data indicate that CB(1) receptor levels are significantly reduced in mSOD1 mice having partial deletion of BiP gene. |
format | Online Article Text |
id | pubmed-8621319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86213192021-11-27 BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis Gómez-Almería, Marta Burgaz, Sonia Costas-Insua, Carlos Rodríguez-Cueto, Carmen Santos-García, Irene Rodríguez-Crespo, Ignacio García, Concepción Guzmán, Manuel de Lago, Eva Fernández-Ruiz, Javier Int J Mol Sci Article In the present study, we investigated the involvement of the chaperone protein BiP (also known as GRP78 or Hspa5), a master regulator of intracellular proteostasis, in two mouse models of neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). To this end, we used mice bearing partial genetic deletion of the BiP gene (BiP(+/−) mice), which, for the ALS model, were crossed with mutant SOD1 (mSOD1) transgenic mice to generate mSOD1/BiP(+/−) double mutant mice. Our data revealed a more intense neurological decline in the double mutants, reflected in a greater deterioration of the neurological score and rotarod performance, with also a reduced animal survival, compared to mSOD1 transgenic mice. Such worsening was associated with higher microglial (labelled with Iba-1 immunostaining) and, to a lesser extent, astroglial (labelled with GFAP immunostaining) immunoreactivities found in the double mutants, but not with a higher loss of spinal motor neurons (labelled with Nissl staining) in the spinal cord. The morphological analysis of Iba-1 and GFAP-positive cells revealed a higher presence of activated cells, characterized by elevated cell body size and shorter processes, in double mutants compared to mSOD1 mice with normal BiP expression. In the case of the PD model, BiP(+/−) mice were unilaterally lesioned with the parkinsonian neurotoxin 6-hydroxydopamine (6-OHDA). In this case, however, we did not detect a greater susceptibility to damage in mutant mice, as the motor defects caused by 6-OHDA in the pole test and the cylinder rearing test, as well as the losses in tyrosine hydroxylase-containing neurons and the elevated glial reactivity (labelled with CD68 and GFAP immunostaining) detected in the substantia nigra were of similar magnitude in BiP(+/−) mice compared with wildtype animals. Therefore, our findings support the view that a dysregulation of the protein BiP may contribute to ALS pathogenesis. As BiP has been recently related to cannabinoid type-1 (CB(1)) receptor function, our work also opens the door to future studies on a possible link between BiP and the neuroprotective effects of cannabinoids that have been widely reported in this neuropathological context. In support of this possibility, preliminary data indicate that CB(1) receptor levels are significantly reduced in mSOD1 mice having partial deletion of BiP gene. MDPI 2021-11-20 /pmc/articles/PMC8621319/ /pubmed/34830414 http://dx.doi.org/10.3390/ijms222212533 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gómez-Almería, Marta Burgaz, Sonia Costas-Insua, Carlos Rodríguez-Cueto, Carmen Santos-García, Irene Rodríguez-Crespo, Ignacio García, Concepción Guzmán, Manuel de Lago, Eva Fernández-Ruiz, Javier BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis |
title | BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis |
title_full | BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis |
title_fullStr | BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis |
title_full_unstemmed | BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis |
title_short | BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis |
title_sort | bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621319/ https://www.ncbi.nlm.nih.gov/pubmed/34830414 http://dx.doi.org/10.3390/ijms222212533 |
work_keys_str_mv | AT gomezalmeriamarta bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT burgazsonia bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT costasinsuacarlos bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT rodriguezcuetocarmen bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT santosgarciairene bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT rodriguezcrespoignacio bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT garciaconcepcion bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT guzmanmanuel bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT delagoeva bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis AT fernandezruizjavier bipheterozigosityaggravatespathologicaldeteriorationinexperimentalamyotrophiclateralsclerosis |